| Identification | Back Directory | [Name]
Ethanesulfonic acid, 2-hydroxy-, compd. with 5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediamine (1:1) | [CAS]
82935-04-4 | [Synonyms]
NSC328564
NSC-328564
NSC 328564
JB-11 isethionate
Ethanesulfonic acid, 2-hydroxy-, compd. with 5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediamine (1:1) | [Molecular Formula]
C21H29N5O7S | [MOL File]
82935-04-4.mol | [Molecular Weight]
495.55 |
| Hazard Information | Back Directory | [Uses]
Trimetrexate (CI-898) isethionate is an antibiotic, also a potent and orally active dihydrofolate reductase (DHFR) inhibitor, reducing the production of DNA and RNA precursors and leading to cell death, with IC50 values of 4.74 nM and 1.35 nM for human DHFR and Toxoplasma gondii DHFR. Trimetrexate isethionate can also inhibit the growth of various cancer cells. Trimetrexate isethionate can be used for researching Pneumocystis carinii pneumonia (PCP) and cancer[1][2][3][4][5]. | [in vivo]
Trimetrexate (180 mg/kg or 30 mg/kg; p.o. or i.p.; daily) isethionate extends the median survival of the toxoplasma infected mice and shows antitoxoplasma activity[3].
Trimetrexate (0-30 mg/kg; i.v.; once daily for 5days) isethionate shows chronic toxicity in rats[4]. | Animal Model: | Toxoplasma infected female BALB/c mice weighing about 20 g[3] | | Dosage: | 180 mg/kg or 30 mg/kg | | Administration: | 180 mg/kg per day orally in the drinking water or 30 mg/kg per day i.p. | | Result: | Extended the median survival of the infected mice to 10 d (p.o.) or 19 d (i.p.). |
| Animal Model: | Charles River Wistar Crl(WI)BR rats weighing approximately 150 to 200 g[4] | | Dosage: | 0, 1, 10, or 30 mg/kg | | Administration: | Intravenous injection, once daily for 5 consecutive days followed by a 23-day recovery period | | Result: | Showed chronic toxicity, the testicular changes persisting during the course of multiple cycles of dosing were not reversible within 21 days, but required an additional 56 days for essentially complete recovery. |
| [IC 50]
Toxoplasma | [References]
[1] Hopper AT, et al. Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis. J Med Chem. 2019 Feb 14;62(3):1562-1576. DOI:10.1021/acs.jmedchem.8b01754
[2] Fulton, B., et al. Trimetrexate. Drugs 49, 563–576 (1995). DOI:10.2165/00003495-199549040-00007
[3] Allegra CJ, et al. Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate. J Clin Invest. 1987 Feb;79(2):478-82. DOI:10.1172/JCI112837
[4] Dethloff LA, et al. Chronic toxicity of the anticancer agent trimetrexate in rats. Fundam Appl Toxicol. 1992 Jul;19(1):6-14. DOI:10.1016/0272-0590(92)90022-a
[5] Grem JL, Voeller DM, Geoffroy F, Horak E, Johnston PG, Allegra CJ. Determinants of trimetrexate lethality in human colon cancer cells. Br J Cancer. 1994 Dec;70(6):1075-84. DOI:10.1038/bjc.1994.451 |
|
|